Advantages of every-3-week dosing of erythropoietic agents to manage chemotherapy-induced anemia

被引：0
|
作者：
Clark, Joan [1 ]
Schergen, Aluin [1 ]
机构：
[1] St Louis Hematol Oncol Specialists Inc, St Louis, MO USA
来源：
ONCOLOGY-NEW YORK | 2006年 / 20卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：795 / 800
页数：6
相关论文
共 50 条
  • [1] Medical cost considerations of fixed dosing regimens of erythropoietic agents in patients with chemotherapy-induced anemia
    Lefebvre, P.
    Vekeman, F.
    Duh, M.
    Watson, S.
    Mckenzie, R. S.
    VALUE IN HEALTH, 2007, 10 (03) : A128 - A128
  • [2] Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia
    Canon, JL
    Vansteenkiste, J
    Bodoky, G
    Mateos, MV
    Bastit, L
    Ferreira, J
    Rossi, G
    Amado, RG
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (04): : 273 - 284
  • [3] Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia
    Hernandez, Enrique
    Ganly, Peter
    Charu, Veena
    DiBenedetto, Joseph
    Tomita, Dianne
    Lillie, Tom
    Taylor, Kerry
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (09) : 2109 - 2120
  • [4] Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia
    Muller, Raymond J.
    Baribeault, David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (24) : 2547 - 2556
  • [5] Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis
    Rosberg, J
    Oster, EF
    Wu, EQ
    Fastenau, J
    Piech, CT
    VALUE IN HEALTH, 2003, 6 (03) : 229 - 230
  • [6] Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA).
    Rearden, TP
    Charu, V
    Saidman, B
    Ben-Jacob, A
    Justice, GR
    Manaim, AS
    Tomita, D
    Rossi, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 745S - 745S
  • [7] Results of a randomized study of every three-week dosing (Q3W) of Darbepoetin alfa for chemotherapy-induced anemia (CIA).
    Rearden, T
    Charu, V
    Saidman, B
    Ben-Jacob, A
    Justice, GR
    Manaim, AS
    Katz, D
    Tomita, D
    Rossi, G
    BLOOD, 2003, 102 (11) : 20B - 21B
  • [8] Management of chemotherapy-induced anemia in patients with lung cancer (LC): A comparative study of erythropoietic agents
    Tiotiu, Angelica
    Clement-Duchene, Christelle
    Vaillant, Pierre
    Barbier, Pauline
    Tiotiu, Decebal
    Martinet, Yves
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [9] Effects of intravenous (IV) iron supplementation on responses to every-3-week (Q3W) darbepoetin alfa (DA) by baseline hemoglobin in patients (pts) with chemotherapy-induced anemia (CIA)
    Pinter, T.
    Mossman, T.
    Suto, T.
    Vansteenkiste, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Rapid correction of anemia with darbepoetin alfa once every 3 weeks in chemotherapy-induced anemia
    Grangeia, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 384 - 385
12345